Research programme: antiviral therapeutics - Celdara Medical/University of Vermont
Latest Information Update: 28 Sep 2022
At a glance
- Originator Celdara Medical; University of Vermont
- Class Antibodies; Antivirals
- Mechanism of Action Immunomodulators; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Viral infections
- No development reported Hantavirus infections; Viral haemorrhagic fevers
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for research development in Hantavirus-infections in USA (Parenteral)
- 28 Sep 2022 No recent reports of development identified for research development in Hantavirus-infections(Prevention) in USA (Parenteral)
- 28 Sep 2022 No recent reports of development identified for research development in Viral-haemorrhagic-fevers in USA